| __timestamp | Novavax, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19928000 | 504755000 |
| Thursday, January 1, 2015 | 30842000 | 838526000 |
| Friday, January 1, 2016 | 46527000 | 1177697000 |
| Sunday, January 1, 2017 | 34451000 | 1320433000 |
| Monday, January 1, 2018 | 34409000 | 1556200000 |
| Tuesday, January 1, 2019 | 34417000 | 1834800000 |
| Wednesday, January 1, 2020 | 145290000 | 1346000000 |
| Friday, January 1, 2021 | 298358000 | 1824900000 |
| Saturday, January 1, 2022 | 488691000 | 2115900000 |
| Sunday, January 1, 2023 | 468946000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Unleashing the power of data
In the competitive world of biotechnology, understanding the financial strategies of industry leaders is crucial. Regeneron Pharmaceuticals, Inc. and Novavax, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Regeneron, a giant in the field, consistently outspent Novavax, with its SG&A expenses peaking at approximately $2.63 billion in 2023, a staggering 460% increase from 2014. In contrast, Novavax's expenses grew more modestly, reaching around $469 million in 2023, marking a 2,256% increase from its 2014 figures. This disparity highlights Regeneron's aggressive investment in administrative and sales functions, possibly reflecting its expansive market reach and product portfolio. Meanwhile, Novavax's leaner approach may indicate a focus on strategic growth and innovation. These financial trajectories offer a window into each company's operational priorities and market strategies.
Eli Lilly and Company and Novavax, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: AstraZeneca PLC vs Regeneron Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Summit Therapeutics Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Intra-Cellular Therapies, Inc. Trends and Insights
Regeneron Pharmaceuticals, Inc. vs Axsome Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs ImmunityBio, Inc.
Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and Novavax, Inc.
Catalent, Inc. or Novavax, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs Novavax, Inc. Trends and Insights
Rhythm Pharmaceuticals, Inc. or Novavax, Inc.: Who Manages SG&A Costs Better?